Earth Times reports that researchers from Duke University and Aldagen, Inc. presented results of preclinical studies at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. The company is developing a stem cell therapy product called ALD-101, which is expected to reduce the time to engraftment following cord blood transplants. Engraftment is when the new stem cells start to grow in the body.
Aldagen’s proprietary technology isolates cells from an enzyme called aldehyde dehydrogenase, or ALDH, found in adult stem cells. Using these cells derived from human cord blood, the company was able to reduce the time to engraftment in mice.
Aldagen is currently conducting a Phase 3 clinical trial of ALD-101 to evaluate its efficacy in accelerating the engraftment in children undergoing umbilical cord blood transplants for the treatment of inherited metabolic diseases.